Lenmed Health Pty Ltd has acquired Mediclinic Kathu Pvt Hospital
Lenmed Health Pty Ltd has acquired the Mediclinic Kathu Pvt Hospital from Mediclinic Southern Africa for US$2 million.
Lenmed Health is an established black-owned hospital group in South Africa, operating multi-specialty hospital facilities in South Africa, Mozambique and Botswana and managing in excess of 1,300 beds.
The Mediclinic Kathu private hospital is situated in the iron ore capital of the Northern Cape between Upington and Vryburg.
Mediclinic Southern Africa is a private hospital group operating in South Africa and Namibia, focused on providing acute care, specialist-orientated, multi-disciplinary hospital services and related service offerings. The group currently operates 49 private hospitals in South Africa and 3 in Namibia, with more than 7,000 beds in total. Mediclinic Southern Africa is a wholly owned subsidiary of the South Africa-based international private healthcare group Mediclinic International, founded in 1983 and listed on the JSE since 1986.
Oaklins' team in South Africa advised the buyer in this transaction.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more